(:BSTC)

Dec 02, 2020 08:09 am ET
BioSpecifics Announces Completion of Acquisition by Endo Pharmaceuticals
WILMINGTON, Del., Dec. 2, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX® in North America, today announced the successful completion of its acquisition by Endo International plc (Endo) for approximately $658.2 million in equity value.
Nov 18, 2020 07:00 am ET
Endo Announces Expiration Of Hart-Scott-Rodino Waiting Period For BioSpecifics Tender Offer
DUBLIN, Nov. 18, 2020 /CNW/ -- Endo International plc (Nasdaq: ENDP) ("Endo") today announced the expiration of the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), in connection with the previously announced tender offer by Beta Acquisition Corp., a wholly-owned indirect subsidiary of Endo ("Merger Sub"), to acquire all of the outstanding shares of common stock, par value $0.001 per share (the "Shares") of BioSpecifics Technologies Corp. (Nasdaq: BSTC) ("BioSpecifics"), at a price of $88.50 per Share (the "Offer Price"), net
Nov 18, 2020 07:00 am ET
Endo Announces Expiration Of Hart-Scott-Rodino Waiting Period For BioSpecifics Tender Offer
DUBLIN, Nov. 18, 2020 /PRNewswire/ -- Endo International plc (Nasdaq: ENDP) ("Endo") today announced the expiration of the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), in connection with the previously announced tender offer by Beta Acquisition Corp., a wholly-owned indirect subsidiary of Endo ("Merger Sub"), to acquire all of the outstanding shares of common stock, par value $0.001 per share (the "Shares") of BioSpecifics Technologies Corp. (Nasdaq: BSTC) ("BioSpecifics"), at a price of $88.50 per Share (the "Offer Price
Nov 18, 2020 12:01 am ET
BioSpecifics Merger Investigation: Halper Sadeh LLP Encourages BioSpecifics Technologies Corp. Shareholders to Contact the Firm – BSTC
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating BioSpecifics Technologies Corp. (NASDAQ: BSTC) and its board of directors for possible breaches of fiduciary duty and other violations of the federal securities laws...
Nov 17, 2020 07:34 pm ET
Nov 13, 2020 10:29 pm ET
SHAREHOLDER ALERT: Halper Sadeh LLP Reminds Shareholders About Its Ongoing Investigations; Investors are Encouraged to Contact the Firm – BSTC, PE, PNM, CEIX
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: BioSpecifics Technologies Corp. (NASDAQ: BSTC) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its...
Nov 12, 2020 12:31 pm ET
INVESTIGATION ALERT: Halper Sadeh LLP Reminds Shareholders About Its Ongoing Merger Investigations; Investors are Encouraged to Contact the Firm - CIT, CXO, BSTC, CBLI, PNM
NEW YORK, Nov. 12, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating:
Nov 10, 2020 07:25 pm ET
Nov 10, 2020 05:46 pm ET
Rigrodsky & Long, P.A. Reminds Investors Of Investigation of BioSpecifics Technologies Corp. Buyout
Rigrodsky & Long, P.A. announces that it is investigating BioSpecifics Technologies Corp. (“BioSpecifics”) (NASDAQ GM: BSTC) regarding possible breaches of fiduciary duties and other violations of law related to BioSpecifics’ agreement to be...
Nov 10, 2020 06:00 am ET
SHAREHOLDER ALERT: Barr Law Group Investigating ZM, CBLI, BSTC, QSR; Shareholders are Encouraged to Contact the Firm
National law firm Barr Law Group is investigating Zoom Video Communications, Inc., Cleveland BioLabs, Inc., BioSpecifics Technologies Corp., and Restaurant Brands International. Shareholders are encouraged to contact [email protected] or call (619)...
Nov 09, 2020 07:00 am ET
BioSpecifics Reports Third Quarter 2020 Financial and Operating Results
WILMINGTON, Del., Nov. 9, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC) ("BioSpecifics" or the "Company"), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX® in North America, today announced its financial results for the third quarter ended September 30, 2020.  
Nov 06, 2020 12:26 pm ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors Of Investigation of BioSpecifics Technologies Corp. Buyout
WILMINGTON, Del., Nov. 6, 2020 /PRNewswire/ -- Rigrodsky & Long, P.A. announces that it is investigating BioSpecifics Technologies Corp. ("BioSpecifics") (NASDAQ GS: BSTC) regarding possible breaches of fiduciary duties and other violations of law related to BioSpecifics' agreement to be acquired by Endo International plc (NASDAQ GS: ENDP).  Under the terms of the agreement, BioSpecifics' shareholders will receive $88.50 per share in cash.
Nov 06, 2020 09:43 am ET
ALERT: Halper Sadeh LLP Investigates the Following Mergers; Investors are Encouraged to Contact the Firm – CXO, BSTC, CBLI, PE
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: Concho Resources Inc. (NYSE: CXO) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to...
Nov 05, 2020 02:28 pm ET
Nov 05, 2020 02:22 pm ET
Moore Kuehn Encourages TNAV, PRCP, ALSK, and BSTC Investors to Contact Law Firm
Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.   Moore Kuehn may seek...
Nov 04, 2020 05:12 pm ET
Lifshitz Law Firm, P.C. Announces Investigation of BioSpecifics Technologies Corp., Cleveland BioLabs, Inc., Concho Resources Inc., and CONSOL Energy Inc.
BioSpecifics Technologies Corp. (NASDAQ: BSTC) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of BSTC to Endo International plc for $88.50 per share. If you are a BSTC...
Nov 04, 2020 11:36 am ET
SHAREHOLDER ALERT: Halper Sadeh LLP Reminds Shareholders About Its Ongoing Merger Investigations; Investors are Encouraged to Contact the Firm - EIGI, TNAV, ALSK, BSTC, CXO
NEW YORK, Nov. 4, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating:
Nov 03, 2020 06:41 pm ET
Nov 03, 2020 05:36 pm ET
BIOSPECIFICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioSpecifics Technologies Corp. - BSTC
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of BioSpecifics Technologies Corp. (NasdaqGS: BSTC) to Endo International plc (NasdaqGS: ENDP). Under the terms of the proposed transaction, shareholders of BioSpecifics will receive only $88.50 in cash for each share of BioSpecifics that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Nov 03, 2020 01:15 pm ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of BSTC, CBMG, CIT, and STND Buyouts
Rigrodsky & Long, P.A. announces that it is investigating: BioSpecifics Technologies Corp. (NASDAQ GS: BSTC) regarding possible breaches of fiduciary duties and other violations of law related to BioSpecifics Technologies’ agreement to be acquired...
Nov 03, 2020 11:23 am ET
Moore Kuehn Encourages BSTC, DNKN, EIGI, and PRCP Investors to Contact Law Firm
NEW YORK, Nov. 3, 2020 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.  Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies:
Nov 02, 2020 08:13 am ET
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of BioSpecifics Technologies Corp. - BSTC
NEW YORK, Oct. 30, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating BioSpecifics Technologies Corp. ("BioSpecifics" or the "Company") (BSTC) relating to its proposed acquisition by Endo International PLC. Under the terms of the agreement, BioSpecifics shareholders will receive $88.50 per share in cash.
Nov 02, 2020 06:00 am ET
Endo International plc Commences Tender Offer for All Outstanding Shares of BioSpecifics Technologies Corp.
DUBLIN, Nov. 2, 2020 /CNW/ -- Endo International plc (Nasdaq: ENDP) ("Endo") today announced that Endo's wholly-owned indirect subsidiary, Beta Acquisition Corp. ("Merger Sub"), has commenced its previously announced tender offer to acquire all of the outstanding shares of common stock, par value $0.001 per share (the "Shares") of BioSpecifics Technologies Corp. (Nasdaq: BSTC) ("BioSpecifics"), at a price of $88.50 per Share, net to the holder in cash, without interest and less any applicable withholding taxes (the "Offer"). The Offer is being made pursuant to the Agreement and Plan of Merge
Nov 02, 2020 06:00 am ET
Endo International plc Commences Tender Offer for All Outstanding Shares of BioSpecifics Technologies Corp.
DUBLIN, Nov. 2, 2020 /PRNewswire/ -- Endo International plc (Nasdaq: ENDP) ("Endo") today announced that Endo's wholly-owned indirect subsidiary, Beta Acquisition Corp. ("Merger Sub"), has commenced its previously announced tender offer to acquire all of the outstanding shares of common stock, par value $0.001 per share (the "Shares") of BioSpecifics Technologies Corp. (Nasdaq: BSTC) ("BioSpecifics"), at a price of $88.50 per Share, net to the holder in cash, without interest and less any applicable withholding taxes (the "Offer"). The Offer is being made pursuant to the Agreement and Plan o
Oct 27, 2020 05:00 pm ET
MERGER ALERT - BSTC, BBIO, and PNM: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
NEW YORK, NY / ACCESSWIRE / October 23, 2020 / The following statement is being issued by Levi & Korsinsky, LLP:
Oct 26, 2020 03:02 pm ET
BIOSPECIFICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioSpecifics Technologies Corp. - BSTC
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of BioSpecifics Technologies Corp. (NasdaqGS: BSTC) to Endo International plc (NasdaqGS: ENDP). Under the terms of the proposed transaction, shareholders of BioSpecifics will receive only $88.50 in cash for each share of BioSpecifics that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Oct 26, 2020 01:36 pm ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of CXO, BSTC, CIT, and EIDX Mergers
Rigrodsky & Long, P.A. announces that it is investigating: Concho Resources Inc. (NYSE: CXO) regarding possible breaches of fiduciary duties and other violations of law related to Concho Resources’ agreement to be acquired by ConocoPhillips....
Oct 21, 2020 04:16 pm ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of CXO, BSTC, MYOK, and CBMG Mergers
Rigrodsky & Long, P.A. announces that it is investigating: Concho Resources Inc. (NYSE: CXO) regarding possible breaches of fiduciary duties and other violations of law related to Concho Resources’ agreement to be acquired by ConocoPhillips. Under...
Oct 21, 2020 11:46 am ET
Moore Kuehn Encourages MYOK, BSTC, CIT, and PE and Investors to Contact Law Firm
Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may ultimately seek...
Oct 21, 2020 10:25 am ET
MERGER ALERT - CIT and BSTC: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
NEW YORK, NY / ACCESSWIRE / October 21, 2020 / The following statement is being issued by Levi & Korsinsky, LLP:
Oct 21, 2020 10:20 am ET
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of BioSpecifics Technologies Corp. - BSTC
NEW YORK, Oct. 20, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating BioSpecifics Technologies Corp. ("BioSpecifics" or the "Company") (BSTC) relating to its proposed acquisition by Endo International PLC. Under the terms of the agreement, BioSpecifics shareholders will receive $88.50 per share in cash.
Oct 20, 2020 03:07 pm ET
SHAREHOLDER ALERT: Halper Sadeh LLP is Investigating the Following Companies; Investors are Encouraged to Contact the Firm - CXO, RESI, BSTC
NEW YORK, Oct. 20, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating:
Oct 19, 2020 01:50 pm ET
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of BioSpecifics Technologies Corp.
NEW YORK, Oct. 19, 2020 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by BioSpecifics Technologies Corp. (NASDAQ: BSTC) and its board of directors concerning the proposed acquisition of the company by Endo International plc (NASDAQ: ENDP). Stockholders will receive $88.50 for each share of BioSpecifics Technologies stock that they hold. The transaction is valued at approximately $658 million and is expected to close in the fourth quarter of 2020.
Oct 19, 2020 01:14 pm ET
BIOSPECIFICS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of BSTC and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of BioSpecifics Technologies Corp. (NASDAQ: BSTC) breached their fiduciary duties or violated the federal...
Oct 19, 2020 11:15 am ET
Thinking about buying stock in BioSpecifics Technologies, Front Yard Residential, Edesa Biotech, Cinemark Holdings, or Lithium Americas?
NEW YORK, Oct. 19, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BSTC, RESI, EDSA, CNK, and LAC.
Oct 19, 2020 10:04 am ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of BioSpecifics Technologies Corp. Buyout
Rigrodsky & Long, P.A. announces that it is investigating BioSpecifics Technologies Corp. (“BioSpecifics”) (NASDAQ GS: BSTC) regarding possible breaches of fiduciary duties and other violations of law related to BioSpecifics’ agreement to be...
Oct 19, 2020 09:30 am ET
BioSpecifics Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of BioSpecifics Technologies Corp. Is Fair to Shareholders; Investors Are Encouraged to Contact the Fi
Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of BioSpecifics Technologies Corp. (NASDAQ: BSTC) to Endo International plc for $88.50 per share is fair to BioSpecifics shareholders. On behalf of BioSpecifics shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Oct 19, 2020 07:30 am ET
BioSpecifics to be Acquired by Endo Pharmaceuticals
WILMINGTON, Del., Oct. 19, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC) announced today that it has entered into a definitive merger agreement under which Endo International plc (NASDAQ: ENDP) will acquire BioSpecifics for an estimated equity value of approximately $658.0 million ($540.0 million in enterprise value net of cash on hand), or $88.50 per share in cash. The transaction was unanimously approved by both BioSpecifics' and Endo's Boards of Directors and is anticipated to close during the fourth quarter of 2020.
Oct 19, 2020 07:30 am ET
Endo to Acquire BioSpecifics to Enhance Profitability of XIAFLEX® and Qwo™
-- Endo to acquire BioSpecifics in an accretive all-cash transaction --
Oct 19, 2020 07:30 am ET
Endo to Acquire BioSpecifics to Enhance Profitability of XIAFLEX® and Qwo™
-- Endo to acquire BioSpecifics in an accretive all-cash transaction --
Jul 20, 2020 07:30 am ET
BioSpecifics Appoints Alex Monteith as Chief Business Officer
WILMINGTON, Del., July 20, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC) (the "Company"), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX® in North America, today announced the appointment of Alex Monteith as Senior Vice President and Chief Business Officer.
May 11, 2020 08:05 am ET
BioSpecifics Reports First Quarter 2020 Financial and Operating Results
WILIMINGTON, Del., May 11, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX® in North America, today announced its financial results for the first quarter ended March 31, 2020.  
May 11, 2020 08:00 am ET
BioSpecifics Names Joseph Truitt as Permanent Chief Executive Officer
WILIMINGTON, Del., May 11, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX® in North America, today announced the appointment of Joseph Truitt as Chief Executive Officer. Mr. Truitt was appointed interim Chief Executive Officer by the Company's Board of Directors on April 6, 2020 and assumed this permanent role on May 7, 2020.
Apr 10, 2020 04:00 pm ET
BioSpecifics Adopts Replacement Stockholder Rights Plan
WILMINGTON, Del., April 10, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in North America, today announced that its Board of Directors has adopted a stockholder rights plan to replace BioSpecifics' current rights plan, which has been terminated.  BioSpecifics intends to submit the rights plan, which is similar to rights plans adopted by many other public companies, for stockholder ratification at its 2020
Apr 09, 2020 08:05 am ET
BioSpecifics Appoints Mike Sherman and Corey Fishman to Board of Directors
WILIMINGTON, Del., April 9, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in North America, today announced that its Board of Directors appointed Mike Sherman and Corey Fishman to serve as Independent Directors, effective immediately. Mike Sherman and Corey Fishman will both join the Board's Audit Committee, with Mr. Sherman serving as an "audit committee financial expert." Corey Fishman will also join the
Apr 09, 2020 08:00 am ET
BioSpecifics Appoints Joseph Truitt as Interim Chief Executive Officer
WILIMINGTON, Del., April 9, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX® in North America, today announced that the Board of Directors has appointed Joseph Truitt as interim Chief Executive Officer. He will also serve on the Company's Board of Directors. Mr. Truitt succeeds J. Kevin Buchi, who served as CEO since October 2019, and has departed the company.
Mar 16, 2020 04:01 pm ET
BioSpecifics Reports Fourth Quarter and Full Year 2019 Financial and Operating Results
WILIMINGTON, Del., March 16, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in North America, today announced its financial results for the fourth quarter and full year ended December 31, 2019 and provided a corporate update.  
Nov 08, 2019 07:01 am ET
BioSpecifics Reports Third Quarter 2019 Financial and Operating Results
LYNBROOK, N.Y., Nov. 8, 2019 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced its financial results for the third quarter ended September 30, 2019 and provided a corporate update.  
Oct 10, 2019 08:01 am ET
BioSpecifics Technologies Corp. Names J. Kevin Buchi as Chief Executive Officer
LYNBROOK, N.Y., Oct. 10, 2019 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today named life sciences industry veteran Kevin Buchi chief executive officer of BioSpecifics. He will also serve on the company's board of directors.
Aug 09, 2019 04:01 pm ET
BioSpecifics Technologies Corp. Reports Second Quarter 2019 Financial and Operating Results
LYNBROOK, N.Y., Aug. 9, 2019 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced its financial results for the second quarter ended June 30, 2019 and provided a corporate update.  
May 23, 2019 08:01 am ET
BioSpecifics Technologies Corp. Announces Authorization of up to $4 Million Stock Repurchase Program
LYNBROOK, N.Y., May 23, 2019 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC) ("BioSpecifics"), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced that the Executive Committee of its Board of Directors has authorized a stock repurchase program under which BioSpecifics is authorized to repurchase up to $4 million of its outstanding common stock. This decision reflects BioSpecifics' continued confidence in achieving
May 10, 2019 08:01 am ET
BioSpecifics Technologies Corp. Reports First Quarter 2019 Financial and Operating Results
LYNBROOK, N.Y., May 10, 2019 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced its financial results for the first quarter ended March 31, 2019 and provided a corporate update.  
Apr 02, 2019 08:01 am ET
BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2018 Financial Results
LYNBROOK, N.Y., April 2, 2019 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced its financial results for the fourth quarter and full year ended December 31, 2018 and provided a corporate update.  
Mar 18, 2019 08:01 am ET
BioSpecifics Technologies Corp. Announces Passing of President Thomas L. Wegman
LYNBROOK, N.Y., March 18, 2019 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced with great sadness that Thomas L. Wegman, President of BioSpecifics, passed away on March 13, 2019. Mr. Wegman served as an officer at BioSpecifics for over 20 years and was a member of the Board of Directors since 1994.
Feb 04, 2019 07:35 am ET
Analysis: Positioning to Benefit within Amarin, Retrophin, Sunrun, BioSpecifics Technologies, Arbutus Biopharma, and TOCAGEN INC — Research Highlights Growth, Revenue, and Consolidated Results
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Amarin Corporation PLC (NASDAQ:AMRN), Retrophin, Inc. (NASDAQ:RTRX),...
Nov 28, 2018 08:15 am ET
Market Trends Toward New Normal in Amarin, BioSpecifics Technologies, Cavco Industries, Iconix Brand Group, A-Mark Precious Metals, and Core-Mark Holding — Emerging Consolidated Expectations, Analyst
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Amarin Corporation PLC (NASDAQ:AMRN), BioSpecifics Technologies Corp...
Nov 15, 2018 03:30 pm ET
BioSpecifics Technologies Corp. Appoints Ron Law, Ph.D, J.D., as Senior Vice President of Business Development
LYNBROOK, N.Y., Nov. 15, 2018 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC) a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced that Ron Law, Ph.D., J.D. has been appointed as Senior Vice President of Business Development and will be responsible for strategic partnerships, reporting directly to Thomas L. Wegman, President of BioSpecifics. Dr. Law has been consulting for BioSpecifics since July 15, 2018.
Nov 09, 2018 07:01 am ET
BioSpecifics Technologies Corp. Reports Third Quarter 2018 Financial Results
LYNBROOK, N.Y., Nov. 9, 2018 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced its financial results for the third quarter ended September 30, 2018 and provided a corporate update.
Oct 31, 2018 04:30 pm ET
BioSpecifics Technologies Corp. Announces Positive Topline Results from Phase 1 Study of CCH for the Treatment of Uterine Fibroids
LYNBROOK, N.Y., Oct. 31, 2018 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced positive topline data from its Phase 1 trial of Collagenase Clostridium Histolyticum (CCH) for the treatment of uterine fibroids. The study met the primary endpoint of safety and tolerability with no observed clinically significant adverse reactions. Pharmacodynamic changes were noted i
Oct 19, 2018 08:45 am ET
Investor Expectations to Drive Momentum within Ultrapar Participacoes S.A, BioSpecifics Technologies, GSV Capital, 58, Mitel Networks, and Amarin — Discovering Underlying Factors of Influence
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Ultrapar Participacoes S.A. (NYSE:UGP), BioSpecifics Technologies Corp...
Aug 30, 2018 08:01 am ET
BioSpecifics Technologies Corp. to Present at Two Upcoming September Conferences
LYNBROOK, N.Y., Aug. 30, 2018 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the following upcoming conferences in September.
Aug 21, 2018 08:20 am ET
Market Trends Toward New Normal in Addus HomeCare, Sandstorm Gold, BioSpecifics Technologies, Itau Unibanco Holding S.A, Akers Biosciences, and Kosmos Energy — Emerging Consolidated Expectations, Anal
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Addus HomeCare Corporation (NASDAQ:ADUS), Sandstorm Gold Ltd (NYSE:SAND),...
Aug 09, 2018 08:01 am ET
BioSpecifics Technologies Corp. Reports Second Quarter 2018 Financial Results
LYNBROOK, N.Y., Aug. 9, 2018 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced its financial results for the second quarter ended June 30, 2018 and provided a corporate update.
Jun 06, 2018 07:35 am ET
Investor Expectations to Drive Momentum within Capital Product Partners, Nova Measuring Instruments, BioSpecifics Technologies, Itau Unibanco Holding S.A., CNB Financial, and Laureate Education — Disc
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Capital Product Partners L.P. (NASDAQ:CPLP), Nova Measuring Instruments...
May 09, 2018 08:01 am ET
BioSpecifics Technologies Corp. Reports First Quarter 2018 Financial Results
LYNBROOK, N.Y., May 9, 2018 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced its financial results for the first quarter ended March 31, 2018 and provided a corporate update.
Apr 11, 2018 08:20 am ET
New Research: Key Drivers of Growth for Talend S.A, Chipmos Technologies, POSCO, Horizon Pharma Public, BioSpecifics Technologies, and Arbutus Biopharma — Factors of Influence, Major Initiatives and S
NEW YORK, April 11, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Talend S.A. (NASDAQ:TLND), Chipmos Technologies Ltd....
Mar 16, 2018 08:30 am ET
New Research: Key Drivers of Growth for CNB Financial, Akebia Therapeutics, Mesoblast, 21Vianet Group, Old Line Bancshares, and BioSpecifics Technologies — Factors of Influence, Major Initiatives and
NEW YORK, March 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CNB Financial Corporation (NASDAQ:CCNE), Akebia Therapeutics,...
Mar 14, 2018 08:01 am ET
BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2017 Financial Results
LYNBROOK, N.Y., March 14, 2018 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced its financial results for the fourth quarter and full year ended December 31, 2017 and provided a corporate update.
Mar 12, 2018 04:30 pm ET
BioSpecifics Technologies Corp. Announces Presentation of Interim Data from Phase 1 Study of CCH for the Treatment of Uterine Fibroids at 65th Annual Scientific Meeting of the Society for Reproductive
LYNBROOK, N.Y., March 12, 2018 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced the presentation of interim data from its ongoing Phase 1 trial of Collagenase Clostridium Histolyticum (CCH) for the treatment of uterine fibroids at the 65th Annual Scientific Meeting of the Society for Reproductive Investigation on Friday, March 9, 2018 in San Diego, CA. The data sh
Jan 22, 2018 07:00 am ET
BioSpecifics Technologies Corp. to Present at the NobleCon14 Conference
LYNBROOK, N.Y., Jan. 22, 2018 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the upcoming at NobleCon14 – Noble Capital Markets' Fourteenth Annual Investor Conference in Fort Lauderdale, Florida on Monday, January 29th at 2:00pm E.T. 
Nov 10, 2017 08:00 am ET
BioSpecifics Technologies Corp. Reports Third Quarter 2017 Financial Results
LYNBROOK, N.Y., Nov. 10, 2017 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced its financial results for the third quarter ended September 30, 2017 and provided a corporate update.
Nov 07, 2017 08:01 am ET
BioSpecifics Technologies Corp. to Present at the Stifel 2017 Healthcare Conference
LYNBROOK, N.Y., Nov. 7, 2017 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the upcoming Stifel 2017 Healthcare Conference on Tuesday, November 14, 2017 at 3:30 p.m. ET in New York, NY.
Sep 20, 2017 09:00 am ET
BioSpecifics Technologies Corp. to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference
LYNBROOK, N.Y., Sept. 20, 2017 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the upcoming 2017 Cantor Fitzgerald Global Healthcare Conference at 2:15 p.m. ET on Wednesday, September 27, 2017 in New York, NY. This is an updated time from what was previously announced in a press releas
Sep 05, 2017 09:00 am ET
BioSpecifics Technologies Corp. to Present at Two Upcoming September Conferences
LYNBROOK, N.Y., Sept. 5, 2017 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the following upcoming conferences.
Aug 09, 2017 05:01 pm ET
BioSpecifics Technologies Corp. Reports Second Quarter 2017 Financial Results
LYNBROOK, N.Y., Aug. 9, 2017 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced its financial results for the second quarter ended June 30, 2017 and provided a corporate update.
Jun 02, 2017 05:05 pm ET
BioSpecifics Technologies Corp. to Present at the Jefferies 2017 Healthcare Conference
LYNBROOK, N.Y., June 2, 2017 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced that management will present a corporate overview at the upcoming Jefferies 2017 Healthcare Conference on Friday, June 9, 2017 at 12:30 p.m. ET in New York, NY.
May 10, 2017 05:05 pm ET
BioSpecifics Technologies Corp. Reports First Quarter 2017 Financial Results
LYNBROOK, N.Y., May 10, 2017 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced its financial results for the first quarter ended March 31, 2017 and provided a corporate update.
Apr 18, 2017 09:00 am ET
BioSpecifics Technologies Corp. Initiates Phase 1 Clinical Trial of XIAFLEX for Treatment of Uterine Fibroids
LYNBROOK, N.Y., April 18, 2017 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced that it has initiated an open-label, dose escalation Phase 1 clinical trial of XIAFLEX for the treatment of uterine fibroids.
Mar 29, 2017 05:30 pm ET
BioSpecifics Technologies Corp. to Present at the 16th Annual Needham Healthcare Conference
LYNBROOK, N.Y., March 29, 2017 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum (CCH) marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced that management will present a corporate overview at the upcoming 16th Annual Needham Healthcare Conference on Wednesday, April 5, 2017 at 8:00 a.m. ET in New York, NY.
Mar 15, 2017 09:00 am ET
BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2016 Financial Results
LYNBROOK, N.Y., March 15, 2017 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum (CCH) marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced its financial results for the fourth quarter and full year ended December 31, 2016 and provided a corporate update.
Jan 24, 2017 04:30 pm ET
BioSpecifics Technologies Corp. to Present at NobleCon13 - Noble Capital Markets' Thirteenth Annual Investor Conference
LYNBROOK, N.Y., Jan. 24, 2017 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the upcoming NobleCon13 - Noble Capital Markets' Thirteenth Annual Investor Conference on Tuesday, January 31, 2017 at 1:00 p.m. ET in Boca Raton, FL.   
Jan 05, 2017 09:00 am ET
The Life Sciences Report Announces 19 Companies Selected for the 2017 Small-Cap Biotech Watchlist
Now in its fifth year, the 2017 Life Sciences Report Biotech Watchlist includes nineteen small-cap biotech companies selected by top analysts in the field, and will be presented at the Biotech Showcase in San Francisco on January 11. Included in...
Nov 17, 2016 04:05 pm ET
BioSpecifics Technologies Corp. Announces Positive Data from Phase 2b Study of CCH in Patients with Cellulite
LYNBROOK, N.Y., Nov. 17, 2016 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX® in the U.S. and Xiapex® in Europe today announced positive, highly statistically significant results from a Phase 2b study of CCH for the treatment of cellulite, or edematous fibrosclerotic panniculopathy. Trial subjects receiving CCH showed statistically significant levels of improvement in
Nov 09, 2016 04:05 pm ET
BioSpecifics Technologies Corp. Reports Third Quarter 2016 Financial Results
LYNBROOK, N.Y., Nov. 9, 2016 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX® in the U.S. and Xiapex® in Europe announced today its financial results for the third quarter ended September 30, 2016 and provided a corporate update.
Nov 08, 2016 08:00 am ET
BioSpecifics Technologies Corp. to Present at Stifel 2016 Healthcare Conference
LYNBROOK, N.Y., Nov. 8, 2016 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the upcoming Stifel 2016 Healthcare Conference on Tuesday, November 15, 2016 at 8:00 a.m. ET in New York, NY.   
Nov 02, 2016 09:00 am ET
BioSpecifics Technologies Corp. to Report Third Quarter 2016 Financial Results on Wednesday, November 9, 2016
LYNBROOK, N.Y., Nov. 2, 2016 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX® in the U.S. and Xiapex® in Europe announced today that it will host a conference call and live audio webcast at 5:00 p.m. ET on Wednesday, November 9, 2016 to report its third quarter 2016 financial results and to provide a corporate update.
Sep 02, 2016 09:00 am ET
BioSpecifics Technologies Corp. to Present at Two Upcoming September Conferences
LYNBROOK, N.Y., Sept. 2, 2016 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the following upcoming conferences.
Aug 09, 2016 05:05 pm ET
BioSpecifics Technologies Corp. Reports Second Quarter 2016 Financial Results
LYNBROOK, N.Y., Aug. 9, 2016 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced its financial results for the second quarter ended June 30, 2016 and provided a corporate update.
Aug 02, 2016 09:00 am ET
BioSpecifics Technologies Corp. to Report Second Quarter 2016 Financial Results on Tuesday, August 9, 2016
LYNBROOK, N.Y., Aug. 2, 2016 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, announced today that it will host a conference call and live audio webcast at 4:30 p.m. ET on Tuesday, August 9, 2016 to report its second quarter 2016 financial results and to provide a corporate update.
Jun 13, 2016 08:30 am ET
BioSpecifics Technologies Corp. Announces Positive Top-Line Results from Phase 2 Trial of CCH for Treatment of Human Lipoma
LYNBROOK, N.Y., June 13, 2016 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC) today announced positive, statistically significant top-line results from a placebo-controlled, double-blind Phase II clinical trial of collagenase clostridium histolyticum (CCH) for the treatment of human lipoma. The trial met its primary endpoint of reduction in the visible surface area of the target lipomas relative to placebo, as determined by caliper, at six months post injection (p<0.0001), and also met all secondary efficacy endpoints. There were no serious adverse events reported during th
Jun 02, 2016 08:30 am ET
BioSpecifics Technologies Corp. to Present at the Jefferies 2016 Healthcare Conference
LYNBROOK, N.Y., June 2, 2016 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the upcoming Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 at 8:00 a.m. ET in New York, NY.   
May 31, 2016 08:30 am ET
BioSpecifics Technologies Corp. Announces Publication of Encouraging Data for Uterine Fibroid Treatment with CCH in American Journal of Obstetrics & Gynecology
LYNBROOK, N.Y., May 31, 2016 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced the publication of data highlighting the efficacy of collagenase clostridium histolyticum (CCH) for the treatment of uterine fibroids in the May 2016 issue of the American Journal of Obstetrics & Gynecology in an article titled, "Loss of Stiffness in Collagen-Rich Uterine Fibroids af
May 18, 2016 08:30 am ET
BioSpecifics Technologies Corp. to Present at the 2016 UBS Global Healthcare Conference
LYNBROOK, N.Y., May 18, 2016 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the upcoming 2016 UBS Global Healthcare Conference on Tuesday, May 24, 2016 at 3:00 p.m. ET in New York, NY.   
May 10, 2016 08:30 am ET
BioSpecifics Technologies Corp. Reports First Quarter 2016 Financial Results
LYNBROOK, N.Y., May 10, 2016 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced its financial results for the first quarter ended March 31, 2016 and provided a corporate update.
May 03, 2016 09:00 am ET
BioSpecifics Technologies Corp. to Report First Quarter 2016 Financial Results on Tuesday, May 10, 2016
LYNBROOK, N.Y., May 3, 2016 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, announced today that it will host a conference call and live audio webcast at 8:30 a.m. ET on Tuesday, May 10, 2016 to report its first quarter 2016 financial results and to provide a corporate update.
Apr 06, 2016 09:00 am ET
BioSpecifics Technologies Corp. to Present at the 15th Annual Needham Healthcare Conference
LYNBROOK, N.Y., April 6, 2016 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, announced today that BioSpecifics' President, Tom Wegman, will present a corporate overview at the upcoming 15th Annual Needham Healthcare Conference on Wednesday, April 13, 2016 at 10:40 a.m. ET in New York, NY.   
Mar 14, 2016 08:00 am ET
BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2015 Financial Results
LYNBROOK, N.Y., March 14, 2016 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced its financial results for the fourth quarter and full year ended December 31, 2015 and provided a corporate update.
Mar 08, 2016 08:00 am ET
BioSpecifics Technologies Corp. to Present at the 28th Annual ROTH Conference
LYNBROOK, N.Y., March 8, 2016 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, announced today that BioSpecifics' President, Tom Wegman, will present a corporate overview at the upcoming 28th Annual ROTH Conference on Tuesday, March 15, 2016 at 12:30 p.m. PT in Dana Point, CA.   
Mar 07, 2016 08:00 am ET
BioSpecifics Technologies Corp. to Report Fourth Quarter and Full Year 2015 Financial Results on Monday, March 14, 2016
LYNBROOK, N.Y., March 7, 2016 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. and Xiapex® in Europe, announced today that it will host a conference call and live audio webcast at 8:30 a.m. ET on Monday, March 14, 2016 to report its fourth quarter and full year 2015 financial results and to provide a corporate update.
Feb 01, 2016 08:00 am ET
BioSpecifics Technologies Corp. to Present at the 2016 BIO CEO & Investor Conference
LYNBROOK, N.Y., Feb. 1, 2016 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. and Xiapex® in Europe, announced today that BioSpecifics' President, Tom Wegman, will present a corporate overview at the upcoming 2016 BIO CEO & Investor Conference on Monday, February 8, 2016 at 11:00 a.m. ET in New York, NY.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.